Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial

Area of Science:

• Nutritional Science
• Endocrinology
• Cardiovascular Medicine

Background:

• Type 2 diabetes (T2D) is a significant risk factor for cardiovascular disease (CVD), often accompanied by dyslipidemia.
• Curcuminoids, natural compounds, possess potential anti-diabetic and lipid-modifying properties.
• Limited research exists on curcuminoids' efficacy in improving dyslipidemia specifically within diabetic populations.

Purpose of the Study:

• To evaluate the effectiveness of curcuminoid supplementation, enhanced by piperine, on serum lipid profiles in patients diagnosed with T2D.
• To assess the impact of curcuminoids on key lipid and lipoprotein concentrations relevant to cardiovascular health.

Main Methods:

• A 12-week randomized, double-blind, placebo-controlled trial involving 118 T2D patients.
• Participants received either 1000mg/day curcuminoids + 10mg/day piperine or a placebo, alongside standard T2D care.
• Serum lipid levels (TC, LDL-C, HDL-C, TG, Lp(a), non-HDL-C) were measured at baseline and study completion.

Main Results:

• The curcuminoids group showed significant reductions in total cholesterol (TC), non-HDL-C, and lipoprotein(a) [Lp(a)] compared to placebo.
• A statistically significant increase in high-density lipoprotein cholesterol (HDL-C) was observed in the curcuminoids group.
• No significant differences were found in serum triglycerides (TG) or low-density lipoprotein cholesterol (LDL-C) between the groups.

Conclusions:

• Curcuminoid supplementation effectively reduces serum levels of atherogenic lipid indices, specifically non-HDL-C and Lp(a).
• These findings indicate that curcuminoids may play a role in mitigating cardiovascular event risk for T2D patients experiencing dyslipidemia.
• Piperine enhances curcuminoid absorption, potentially maximizing therapeutic benefits for lipid management.